BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 10868465)

  • 1. Atypical antipsychotics and weight gain--a systematic review.
    Taylor DM; McAskill R
    Acta Psychiatr Scand; 2000 Jun; 101(6):416-32. PubMed ID: 10868465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
    Hilger E; Kasper S
    Wien Klin Wochenschr; 2000 Dec; 112(24):1031-8. PubMed ID: 11204312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Silveira da Mota Neto JI; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006624. PubMed ID: 20091599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of atypical antipsychotics and weight gain.
    Sussman N
    J Clin Psychiatry; 2001; 62 Suppl 23():5-12. PubMed ID: 11603886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the side effect profile of the atypical antipsychotics.
    Alao AO; Malhotra K; Dewan MJ
    West Afr J Med; 2002; 21(4):313-5. PubMed ID: 12665274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psychotropics and weight gain].
    Sahli Ch; Bryois Ch
    Praxis (Bern 1994); 2004 Aug; 93(35):1393-401. PubMed ID: 15468580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Abraham D; Kissling W
    Schizophr Res; 1999 Jan; 35(1):51-68. PubMed ID: 9988841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A typical mood stabilizers: a "typical role for atypical antipsychotics.
    Malhi GS; Berk M; Bourin M; Ivanovski B; Dodd S; Lagopoulos J; Mitchell PB
    Acta Psychiatr Scand Suppl; 2005; (426):29-38. PubMed ID: 16104066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antipsychotics: comparison of weight gain liabilities.
    Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
    J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
    Kuo CJ; Yang SY; Liao YT; Chen WJ; Lee WC; Shau WY; Chang YT; Tsai SY; Chen CC
    Schizophr Bull; 2013 May; 39(3):648-57. PubMed ID: 22282455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
    Geddes J; Freemantle N; Harrison P; Bebbington P
    BMJ; 2000 Dec; 321(7273):1371-6. PubMed ID: 11099280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract]   [Full Text] [Related]  

  • 19. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
    Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
    Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical antipsychotics].
    Naber D
    Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.